| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VAV1 |
| Uniprot No | P15498 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 189-565aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMTEYDKR CCCLREIQQT EEKYTDTLGS IQQHFLKPLQ RFLKPQDIEI IFINIEDLLR VHTHFLKEMK EALGTPGAAN LYQVFIKYKE RFLVYGRYCS QVESASKHLD RVAAAREDVQ MKLEECSQRA NNGRFTLRDL LMVPMQRVLK YHLLLQELVK HTQEAMEKEN LRLALDAMRD LAQCVNEVKR DNETLRQITN FQLSIENLDQ SLAHYGRPKI DGELKITSVE RRSKMDRYAF LLDKALLICK RRGDSYDLKD FVNLHSFQVR DDSSGDRDNK KWSHMFLLIE DQGAQGYELF FKTRELKKKW MEQFEMAISN IYPENATANG HDFQMFSFEE TTSCKACQML LRGTFYQGYR CHRCRASAHK ECLGRVPPCG |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与VAV1重组蛋白相关的3篇参考文献及其简要摘要：
---
1. **"VAV1 mutations in hematopoietic malignancies and autoimmune disease"**
*Authors: B. Tybulevich et al.*
摘要：研究分析了VAV1基因突变在血液系统恶性肿瘤和自身免疫疾病中的作用，利用重组VAV1蛋白验证其突变体对Rho家族GTP酶活性的影响，发现某些突变导致组成性激活的GEF活性，促进细胞异常增殖。
2. **"Structural basis of VAV1 signaling through interaction with the T-cell receptor"**
*Authors: A.V. Miletic et al.*
摘要：通过重组VAV1蛋白的体外表达和结构解析，揭示了VAV1与T细胞受体(TCR)复合物的结合机制，发现其DH结构域对激活下游Rac1信号通路至关重要，并阐明了磷酸化调控的分子细节。
3. **"Functional characterization of recombinant VAV1 in oncogenic signaling"**
*Authors: X.R. Bustelo et al.*
摘要：利用重组VAV1蛋白研究其致癌信号功能，证明其通过调控NFAT/AP-1通路促进T细胞淋巴瘤发展，并发现其PH结构域缺失突变体可增强细胞迁移和侵袭能力。
---
**注**：以上文献为示例性内容，实际文献需通过PubMed/Google Scholar检索确认。如需具体文章，建议使用关键词"VAV1 recombinant protein"或"VAV1 signaling"进一步筛选。
VAV1 is a crucial intracellular signaling protein belonging to the VAV family of guanine nucleotide exchange factors (GEFs). Primarily expressed in hematopoietic cells, it plays a pivotal role in regulating immune responses by activating Rho/Rac GTPases, which modulate cytoskeletal dynamics, gene expression, and cellular activation. Discovered in the 1990s, VAV1 is activated downstream of antigen receptors, such as the T-cell receptor (TCR) and B-cell receptor (BCR), where it mediates signaling pathways critical for lymphocyte development, activation, and differentiation. Its structure includes multiple domains: a calponin homology (CH) domain, an acidic (Ac) region, a Dbl-homology (DH) domain responsible for GEF activity, a pleckstrin homology (PH) domain, and a Src homology 3 (SH3) domain flanked by cysteine-rich motifs. These domains enable interactions with kinases, adaptors, and membrane phospholipids.
Recombinant VAV1 proteins are engineered to study its biochemical functions, interactions, and dysregulation in diseases. Produced via bacterial or eukaryotic expression systems, these purified proteins retain structural and functional properties, allowing in vitro analysis of GEF activity, phosphorylation-dependent regulation, and binding partners. Mutant variants, such as constitutively active forms (e.g., VAV1 oncoproteins with DH domain mutations), are utilized to investigate aberrant signaling in cancers like lymphoma and leukemia. Additionally, recombinant VAV1 aids in drug discovery, serving as a target for inhibitors aiming to modulate immune responses or block oncogenic signaling. Its role in autoimmune disorders and immunodeficiency further underscores its therapeutic relevance. By enabling precise mechanistic studies, VAV1 recombinant proteins remain indispensable tools for unraveling immune signaling networks and developing targeted therapies.
×
